Literature review: impact of developmental and epileptic encephalopathies on caregivers
German burden-of-illness study: quality-of-life outcomes
SCN2A-related disorders: trial-readiness for non-seizure outcomes
SCN2A-related disorders: level of adaptive functioning and change over time
SCN2A-related disorders: implications for choosing trial endpoints
SCN2A-related disorders: gross motor function
SCN2A-related disorders: Vineland-3 growth scale values
SCN2A-related disorders: goal attainment scaling pilot study
Severe neurodevelopmental impairments: meaningful change
SCN8A-related disorders: quality of life and adaptive functioning
SCN8A-related disorders: quality of life and adaptive function by epilepsy phenotype
“Four participants were classified as SeLFIE (21.1%), 8 as mild-to-moderate DEE (42.1%), 6 as DEE (31.6%), and 1 as NDDwGE (5.2%).” (opens the source at this quote in a new tab)
“The SeLFIE group had the highest mean QI-Disability total score (94.2 ± 2.1), followed by mild-to-moderate DEE (80.5 ± 11.6), and then DEE (50.5 ± 14.2); F(2, 15) = 20.13, P < .001” (opens the source at this quote in a new tab)
“Similarly, the SeLFIE group had the highest mean VABS-3 ABC score (103.5 ± 8.6), followed by mild-to-moderate DEE (71.6 ± 4.5), and then DEE (25.5 ± 3.5); F(2, 15) = 49.12, P < .001” (opens the source at this quote in a new tab)
SCN8A-related epilepsy: associations with quality of life and adaptive functioning
Genetic developmental and epileptic encephalopathies: caregiver assessment of quality of life
Severe neurodevelopmental disorders: caregiver-reported quality of life
Genetic developmental and epileptic encephalopathies: non-seizure outcomes and caregiver priorities
Medication-formulation preferences: caregiver survey
SCN8A caregiver priorities: research-roadmap publication